Swiss pharma giant Novartis (NOVN: VX) has announced new post hoc data from the Phase III ASCLEPIOS trials of Kesimpta (ofatumumab).
The data will be presented at the annual meeting of the American Academy of Neurology (AAN), being held virtually between April 17 and April 22.
Novartis said the results further support Kesimpta as a first-choice treatment option for adults with relapsing forms of multiple sclerosis (RMS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze